🚀 VC round data is live in beta, check it out!
CSPC Pharma Group Valuation Multiples
Discover revenue and EBITDA valuation multiples for CSPC Pharma Group and similar public comparables like Zhangzhou Pientzehuang, Alteogen, Neurocrine Biosciences, Jazz Pharmaceuticals and more.
CSPC Pharma Group Overview
About CSPC Pharma Group
CSPC Pharmaceutical Group listed on the Hong Kong Stock Exchange in 1994 and is one of the largest pharmaceutical companies in China. Its biggest business segment is the finished drugs segment which accounts for nearly 80% of its total revenue. Now it has a diversified pipeline portfolio in seven therapeutic areas including nervous system diseases, oncology, anti-infective to cardiovascular disease, respiratory system disease, and metabolism. CSPC also has a bulk drug product segment including vitamin C and antibiotics.
Founded
1992
HQ
Employees
21.4K
Website
Sectors
Financials (LTM)
EV
$12B
CSPC Pharma Group Financials
CSPC Pharma Group reported last 12-month revenue of $4B and EBITDA of $1B.
In the same LTM period, CSPC Pharma Group generated $3B in gross profit, $1B in EBITDA, and $738M in net income.
Revenue (LTM)
CSPC Pharma Group P&L
In the most recent fiscal year, CSPC Pharma Group reported revenue of $4B and EBITDA of $1B.
CSPC Pharma Group expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $4B | XXX | $4B | XXX | XXX | XXX |
| Gross Profit | $3B | XXX | $3B | XXX | XXX | XXX |
| Gross Margin | 68% | XXX | 70% | XXX | XXX | XXX |
| EBITDA | $1B | XXX | $1B | XXX | XXX | XXX |
| EBITDA Margin | 27% | XXX | 24% | XXX | XXX | XXX |
| EBIT Margin | 22% | XXX | 18% | XXX | XXX | XXX |
| Net Profit | $738M | XXX | $635M | XXX | XXX | XXX |
| Net Margin | 18% | XXX | 15% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
CSPC Pharma Group Stock Performance
CSPC Pharma Group has current market cap of $13B, and enterprise value of $12B.
Market Cap Evolution
CSPC Pharma Group's stock price is $1.15.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $12B | $13B | -4.1% | XXX | XXX | XXX | $0.06 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialCSPC Pharma Group Valuation Multiples
CSPC Pharma Group trades at 2.9x EV/Revenue multiple, and 11.1x EV/EBITDA.
EV / Revenue (LTM)
CSPC Pharma Group Financial Valuation Multiples
As of April 18, 2026, CSPC Pharma Group has market cap of $13B and EV of $12B.
Equity research analysts estimate CSPC Pharma Group's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
CSPC Pharma Group has a P/E ratio of 17.7x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $13B | XXX | $13B | XXX | XXX | XXX |
| EV (current) | $12B | XXX | $12B | XXX | XXX | XXX |
| EV/Revenue | 2.9x | XXX | 2.8x | XXX | XXX | XXX |
| EV/EBITDA | 11.1x | XXX | 11.6x | XXX | XXX | XXX |
| EV/EBIT | 13.6x | XXX | 15.1x | XXX | XXX | XXX |
| EV/Gross Profit | 4.3x | XXX | 4.0x | XXX | XXX | XXX |
| P/E | 17.7x | XXX | 20.6x | XXX | XXX | XXX |
| EV/FCF | 13.3x | XXX | 43.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified CSPC Pharma Group Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
CSPC Pharma Group Margins & Growth Rates
CSPC Pharma Group's revenue in the last 12 month grew by 14%.
CSPC Pharma Group's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.
CSPC Pharma Group's rule of 40 is 59% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
CSPC Pharma Group's rule of X is 94% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
CSPC Pharma Group Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 14% | XXX | (11%) | XXX | XXX | XXX |
| EBITDA Margin | 27% | XXX | 24% | XXX | XXX | XXX |
| EBITDA Growth | 41% | XXX | (18%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 59% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 94% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 24% | XXX | 30% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 3% | XXX | 4% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 21% | XXX | 18% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 51% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
CSPC Pharma Group Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| CSPC Pharma Group | XXX | XXX | XXX | XXX | XXX | XXX |
| Zhangzhou Pientzehuang | XXX | XXX | XXX | XXX | XXX | XXX |
| Alteogen | XXX | XXX | XXX | XXX | XXX | XXX |
| Neurocrine Biosciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Jazz Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Ionis Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
CSPC Pharma Group M&A Activity
CSPC Pharma Group acquired XXX companies to date.
Last acquisition by CSPC Pharma Group was on XXXXXXXX, XXXXX. CSPC Pharma Group acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by CSPC Pharma Group
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialCSPC Pharma Group Investment Activity
CSPC Pharma Group invested in XXX companies to date.
CSPC Pharma Group made its latest investment on XXXXXXXX, XXXXX. CSPC Pharma Group invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by CSPC Pharma Group
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout CSPC Pharma Group
| When was CSPC Pharma Group founded? | CSPC Pharma Group was founded in 1992. |
| Where is CSPC Pharma Group headquartered? | CSPC Pharma Group is headquartered in China. |
| How many employees does CSPC Pharma Group have? | As of today, CSPC Pharma Group has over 21K employees. |
| Who is the CEO of CSPC Pharma Group? | CSPC Pharma Group's CEO is Cuilong Zhang. |
| Is CSPC Pharma Group publicly listed? | Yes, CSPC Pharma Group is a public company listed on HKEX. |
| What is the stock symbol of CSPC Pharma Group? | CSPC Pharma Group trades under 01093 ticker. |
| When did CSPC Pharma Group go public? | CSPC Pharma Group went public in 1994. |
| Who are competitors of CSPC Pharma Group? | CSPC Pharma Group main competitors are Zhangzhou Pientzehuang, Alteogen, Neurocrine Biosciences, Jazz Pharmaceuticals. |
| What is the current market cap of CSPC Pharma Group? | CSPC Pharma Group's current market cap is $13B. |
| What is the current revenue of CSPC Pharma Group? | CSPC Pharma Group's last 12 months revenue is $4B. |
| What is the current revenue growth of CSPC Pharma Group? | CSPC Pharma Group revenue growth (NTM/LTM) is 14%. |
| What is the current EV/Revenue multiple of CSPC Pharma Group? | Current revenue multiple of CSPC Pharma Group is 2.9x. |
| Is CSPC Pharma Group profitable? | Yes, CSPC Pharma Group is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of CSPC Pharma Group? | CSPC Pharma Group's last 12 months EBITDA is $1B. |
| What is CSPC Pharma Group's EBITDA margin? | CSPC Pharma Group's last 12 months EBITDA margin is 27%. |
| What is the current EV/EBITDA multiple of CSPC Pharma Group? | Current EBITDA multiple of CSPC Pharma Group is 11.1x. |
| What is the current FCF of CSPC Pharma Group? | CSPC Pharma Group's last 12 months FCF is $890M. |
| What is CSPC Pharma Group's FCF margin? | CSPC Pharma Group's last 12 months FCF margin is 22%. |
| What is the current EV/FCF multiple of CSPC Pharma Group? | Current FCF multiple of CSPC Pharma Group is 13.3x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.